THE DEAL, AT A GLANCE
From the announcementMatchpoint Therapeutics
01What it doesMatchpoint's Advanced Covalent Exploration platform is focused on discovering precision oral medicines to transform the treatment of immune diseases.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedMatchpoint Therapeutics raised Series B, announced 2026-10-07From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersMatchpoint Therapeutics announced a $150 Million Series B financing to advance its pipeline of first-in-class oral small molecules for autoimmune and inflammatory…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Matchpoint Therapeutics · Financing Record
Explore source-linked visual explanations for Matchpoint Therapeutics. Unsupported claims are withheld while source review continues.
Record 13572 · Recorded date: 2026-10-07
Explore company records →